M. Ondrusova

University Hospital Brno, Brno, South Moravian Region, Czech Republic

Are you M. Ondrusova?

Claim your profile

Publications (5)14.86 Total impact

  • Source
    Eva Cesková · Radovan Prikryl · Tomás Kaspárek · Marta Ondrusová
    [Show abstract] [Hide abstract]
    ABSTRACT: One hundred and four male patients hospitalized for the first time with the diagnosis of first-episode schizophrenia were comprehensively assessed on admission and discharge. Psychopathology, treatment response, and remission rates were evaluated (based on the Positive and Negative Syndrome Scale (PANSS), severity of symptoms only). On admission, the most frequently observed symptoms were lack of judgment and insight (87.6%), suspiciousness/feelings of persecution (82.3%), delusions (77%), poor attention (70%), disturbance of volition (65.4%), conceptual disorganization (64.7%), and active social avoidance (64%). Except for delusions and hallucinations, the positive items of the PANSS correlated significantly with negative symptoms, and conceptual disorganization correlated with the greatest number of negative symptoms. Individual negative symptoms were present in about half the patients. At discharge, the most frequent symptoms were again lack of judgment and insight (in 55.7%), and for negative symptoms they were blunted affect (22.1%), emotional withdrawal (21.2%), and passive/apathetic social withdrawal (19.5%). The positive symptoms of suspiciousness/feelings of persecution and grandiosity persisted in 20.6% of patients. On average, all symptoms were significantly reduced 44 days after admission. The negative symptoms improved less, compared with the positive ones. At discharge there was a high rate of responders (response defined as minimal 30% reduction of total PANSS): 73% and 74% of patients fulfilled the criteria for remission. On admission, the responders (n = 76) had significantly higher scores of most symptoms, both positive and negative ones than nonresponders (n = 28).
    Neuropsychiatric Disease and Treatment 07/2005; 1(2):179-85. · 1.74 Impact Factor
  • E Ceskova · R Pkikryl · T Kasparek · M Ondrusova
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTS: To evaluate the risperidone effect on prolactin (PRL) levels and to analyse the relation between PRL change and treatment response in first-episode schizophrenia patients. METHOD: Patients with a first-episode of schizophrenia who were consecutively admitted for hospitalisation participated in a longitudinal follow-up study that included clinical evaluation (PANSS) and PRL assessment. All patients were treated under open conditions with risperidone. RESULTS: Risperidone in an average dose lower than 4 mg significantly improved both positive and negative symptoms. Co-operating responders undergoing maintenance therapy showed a mild trend towards further long-term improvement. At the end of acute treatment the average elevation of PRL levels almost doubled the baseline value. There was a trend among responders to return to their initial values during long-term therapy. Three-quarters of the subjects had hyperprolactinaemia at the end of acute treatment (44 days), and after I year about one-quarter had hyperprolactinaemia. No significant correlation between PRL change and PANSS score change was found. CONCLUSION: There is a considerable variation of PRL elevation among subjects. In some patients the development of tolerance of the PRL-elevating effect was observed. Risperidone-induced changes of PRL levels may not be associated with treatment response.
    International Journal of Psychiatry in Clinical Practice 03/2004; 8(1):31-36. DOI:10.1080/1365150031004786 · 1.39 Impact Factor
  • Schizophrenia Research 03/2003; 60(1):178-179. DOI:10.1016/S0920-9964(03)81065-4 · 3.92 Impact Factor
  • E. Ceskova · B. Prokes · M. Lorenc · P. Drybcak · M. Ondrusova
    European Psychiatry 10/2000; 15. DOI:10.1016/S0924-9338(00)94383-9 · 3.44 Impact Factor
  • E. Cesková · M. Lorenc · P. Drybcak · M. Ondrusová · P. Hrobar
    European Neuropsychopharmacology 09/1999; 9:284-284. DOI:10.1016/S0924-977X(99)80332-0 · 4.37 Impact Factor